TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms

Annals of Hematology

Volumn 91, Issue 4, 2012, Pages 533-541

  Martínez Avilés, Luz ^a,b   Besses, Carlos ^a   Álvarez Larrán, Alberto ^a   Torres, Erica ^a   Serrano, Sergi ^b   Bellosillo, Beatriz ^a,c  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

ASXL1; C CBL; IDH1; IDH2; Mutations; TET2

Indexed keywords

CBL PROTEIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; THROMBOPOIETIN RECEPTOR; ASXL1 PROTEIN, HUMAN; CBL PROTEIN, HUMAN; DNA BINDING PROTEIN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; JAK2 PROTEIN, HUMAN; MPL PROTEIN, HUMAN; ONCOPROTEIN; REPRESSOR PROTEIN; TET2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASXL1 GENE; C CBL GENE; CONTROLLED STUDY; EXON; FEMALE; GENE; GENE FUNCTION; GENE MUTATION; GENETIC CODE; GENETIC IDENTIFICATION; GENOTYPE; HAPLOTYPE; HUMAN; IDH1 GENE; IDH2 GENE; JAK2 GENE; MAJOR CLINICAL STUDY; MALE; MPL GENE; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; PATHOGENESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; TET2 GENE; THROMBOCYTHEMIA; COHORT ANALYSIS; GENETICS; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; EXONS; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; ISOCITRATE DEHYDROGENASE; JANUS KINASE 2; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTORS, THROMBOPOIETIN; REPRESSOR PROTEINS;

EID: 84860824343     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1330-0     Document Type: Article

References (34)

1. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, PatelJ WM et al (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114:144-147
2. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S et al (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289-2301
3. Couronné L, Lippert E, Andrieux J, Kosmider O, Radford-Weiss I, Penther D et al (2009) Analyses of TET2 mutations in postmyeloproliferative neoplasm acute myeloid leukemias. Leukemia 24:201-203
4. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41:838-842
5. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al (2009) TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23:905-911
6. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al (2009) Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 23:900-904
7. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM et al (2009) Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 23:1343-1345
8. Abdel-Wahab (2011) Genetics of the myeloproliferative neoplasms. Curr Opin Hematol 18:117-123
9. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adélaïde J, Rey J et al (2009) Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23:2183-2186
10. Gelsi-Boyer V, Trouplin V, Adélaïde J, Bonansea J, Cervera N, Carbuccia N et al (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematology 145:788-800
11. Abdel-Wahab O, Pardanani A, Patel J, Lasho T, Heguy A, Levine RL et al (2010) Concomitant analysis of EZH2 and ASXL1 Mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Blood (ASH Annual Meeting Abstracts) 116:1267, Abstr. 3070
12. Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay KO et al (2010) Distinct clinical and biological characteristics in adult acute myeloid leukemia bearing isocitrate dehydrogenase 1 (IDH1) mutation. Blood 115:2749-2754
13. Mardis ET, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al (2009) Recurring mutations found by sequencing and acute myeloid leukemia genome. N Engl J Med 361:1058-1066
14. Green A, Beer P (2010) Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 362:369-370
15. Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A (2010) IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 24:1146-1151
16. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D et al (2010) IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24:1302-1309
17. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225-234
18. Sargin B, Choudhary C, Crosetto N, Schmidt MH, Grundler R, Rensinghoff M et al (2007) Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 110:1004-1012
19. Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H et al (2008) 250 K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 68:10349-10357
20. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C et al (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113:6182-6192
21. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S et al (2009) Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 114:1859-1863
22. Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B et al (2009) CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res 215:2238-2247
23. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL et al (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41:446-449
24. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL et al (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41:455-459
25. Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabingir I et al (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41:450-454
26. Olcaydu D, Skoda RC, Looser R, Li S, Cazzola M, Pietra D et al (2009) The 'GGCC'haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 23:1924-1926
27. Jones AV, Campbell PJ, Beer PA, Schnittger S, Vannucchi AM, Zoi K et al (2010) The JAK2 46/1 haplotype predisposes to MPLmutated myeloproliferative neoplasms. Blood 115:4517-4523
28. Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, Bareford D et al (2009) Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115:2891-2900
29. Abdel-Wahab O, Manshouri T, Patel J (2010) Genetic analysis of transforming events that convert chronic myeloproliferative neoplasm to leukemias. Canc Res 70:447-452
30. Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda RC (2010) Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 115:2003-2007
31. Kosmider O, Delabesse, Mansat-De Mas V, Cornillet-Lefebvre P, Blanchet O, Delmer A et al (2011) TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. Haematologica 96:1059-1063
32. Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B et al (2010) Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 28:3858-3865
33. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J, Lea NC, Przychodzen B et al (2010) Next-generation sequencing of the TET2 gene in 355MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 116:3923-3932
34. Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G et al (2011) TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 29:1971-1979